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Introduction
The key task of economic policy is to create favorable conditions for the supply 
of domestic producers in the domestic market as the main source of growth in the 
domestic economy is domestic demand.
An important element of public administration is the management of the phar-
maceutical industry, which figures prominently in both the health care system and 
the economy as a whole. Due to the emergence of dangerous trends that lead to an 
increase in imports against a background of slow economic growth there is a need 
for measures to intensify the policy of import substitution on pharmaceutical market.
Each government should develop a domestic pharmaceutical industry and manu-
facture of medical devices, which would provide public with accessible, high-quality 
medicines and be competitive on the world market.
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1. Import substitution policy of pharmaceutical market
The main goal of the pharmaceutical market is to provide the population with qual-
ity medicines produced domestically. Import substitution is the process of reducing or 
stopping the import of certain goods by their replacement from domestic commodity 
market of the country with similar domestic adequate and with higher consumer charac-
teristics of cost that is not higher than imported ones [Prychodʹko O., 2011]. Thus, import 
substitution strategy conforms to the goal of development of the pharmaceutical market.
In the policy of import substitution almost all protectionist measures can be used 
to make it difficult to make an access of imported goods and services to the internal 
market regulations of foreign trade: the tariff – different kinds of import duties, 
anti-dumping and non-tariff restrictions – licensing, quotas, certification, conscious 
complexity of customs procedures [Žalilo Ja.A., Hacʹko V.M., 2006].
According to Eurostat, the pharmaceutical industry is the undisputed leader among 
the other high-tech industries in the world in terms of creation of gross value added 
per occupied person. In addition, pharmaceutical production accounts for about 19% 
of total R & D expenditure in the world [Eurostat].
The main drawback of import substitution policy is to provide for local businesses 
extremely favorable conditions, protecting against competition. Import substitution 
strategy is also known as “surface industrialization”, because of the absence of com-
petition the motivation to innovate reduces. As a result, protected by the state area 
does not create a demand for qualified personnel, so investments in science lead to 
an increase in the outflow of intelligence abroad [Petrušenko Ju.M., 2013].
It is noteworthy that it is possible to follow the trend, according to which countries 
are adopting a strategy of import substitution in economic recovery and reject it when 
faced with financial difficulties. Import substitution should be a transitional stage in 
the process of economic restructuring and must be used for accelerated moderniza-
tion and development of new trends of the industry, and then gradual transition to 
export-oriented development model should take place, due to the limited domestic 
market and the need to ensure new markets [Enej Ja.I., 2012].
2.  The world experience of import substitution policy implementation  
in pharmaceutical market
Saving the demand of domestic consumers of the goods, the importation of which 
is restricted, creates favorable conditions for the development of the national produc-
tion of its counterparts. Therefore, the policy of import substitution in different time 
periods in more or less obvious form was adopted by the vast majority of the world 
[Žalilo Ja.A., Hacʹko V.M., 2006].
Positive experience in solving the problems of import substitution in the phar-
maceutical field was shown in India. Even 50 years ago, a private pharmaceutical 
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industry in this country was almost absent, the Indian market was full of multinational 
companies that have accumulated 85% of the pharmaceutical market in money equiva-
lent. In 1970, India has taken patent law, there was established a state control over the 
prices on drugs, the program of preferences was implemented in public procurement 
for national producers if they produce medicines of the same quality as imported. 
This led to the rapid growth of the Indian pharmaceutical industries – drugs of lo-
cal production were significantly profitable than imported drugs [Gerster R., 2002]. 
In 2006, the amount of Indian pharmaceutical products in the world was more than 
$ 13 billion, while in 2013 this figure reached $ 22 billion, and by the end of the 
decade analysts predict that it will reach $ 75 billion. According to experts, India is 
the third largest global manufacturer of medical products with an annual growth of 
15–20%. India is the fifth of all of the world’s generics. According to the experts, if 
the rate of development of Indian pharmaceutical industry will remain at this year’s 
level, then in 2020 it will occupy a dominant position in the global pharmaceutical 
market [Paškov V., 2013].
Japan also faced the introduction of the policy of import substitution, and although 
it does not take a leading position in the global pharmaceutical market, with a high 
level of sales, its experience in implementing a policy of import substitution undoubt-
edly deserves attention. Products of Japanese pharmaceutical manufacturers come 
mainly for the domestic market and the export does not exceed 6% of total production. 
It should be noted that local producers offer their products on the domestic market 
at prices that are 10% lower than prices of western analogues but the purchase of 
imported medicinal products is carried out in strict accordance with the needs of the 
population, despite the presence of similar drugs on the market in Japan. This ap-
proach encourages improving the quality of Japanese medicines and development of 
competitive principles of pharmaceutical production products [Klunko N., 2012, p. 28].
Earlier in Russia they built mostly enterprises of “packaging”, which only pack-
aged and marked tablets and solutions, that were imported into the country. However, 
this did not contribute to the development of innovative pharmaceutical business, 
technology transfer and training. Thus, the main priorities have changed for compa-
nies in Russia. For example, to establish production “from scratch”. Import substitu-
tion strategy is realized through localization of production facilities of large foreign 
companies. Also, international companies can count on a variety of preferences in 
public procurement of [Baranovyč M., 2011].
In Russia, foreign pharmaceutical companies are choosing different strategies of 
localization in terms of public policy of import substitution, such as:
• the creation of a strategic alliance for the purpose of production;
• acquisition of existing plants with a view to update them according to the rules 
of GMP, with the transfer of its advanced technology and training;
• transfer of intellectual property rights;
• construction of own factories first of all – for packaging of medicines, and 
eventually a full cycle of production, except the main active ingredient;
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• transfer to the full cycle technology.
The Ukrainian pharmaceutical market depends on import. In monetary terms, the 
share of domestic products is 30%, and the foreign ones – 70%, and in natural – the 
share of domestic production – 65%, and foreign – 35%, respectively. Ukraine has 
experienced a significant loss of market positions of pharmaceutical production – the 
share of consumption of domestic production in terms of money fell from 50% in 
2002 to 29% in 2013, with almost stable consumption in physical terms [Deržavna 
prohrama]. Fig. 1 presents dynamics of export and import of pharmaceutical products 
of Ukraine during 2005–2013.
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Fig. 1. Dynamics of export and import of pharmaceutical products of Ukraine during 2005–2013.
Source: Author’s own study, based on [www.ukrstat.gov.ua ]
As shown in Fig. 1, in Ukraine the volume of imports of pharmaceutical products 
increased in 2005 and 2008 and in 2009–2012, and decreases in 2009 compared to 
2008 to 14.2% and in 2013 compared to the year 2012 to 6.71%. As for exports, its 
volume, with the exception of minor changes (in 2009 it decreased by 0.68% compared 
with 2008, in 2011 – decreased by 1.73% compared to 2010) has steadily increased. 
Overall, Fig. 1. demonstrates a significant excess of total imports of pharmaceutical 
products in Ukraine over exports.
 Numerous problems prevent the development of pharmaceutical industry in 
Ukraine, including: the lack of funding of state development programs of the phar-
maceutical market, the lack of cooperation between government, business and science 
in the creation of complete production cycle of pharmaceutical products, the lack of 
funding for modernization measures in the pharmaceutical industry [Žalilo Ja.A., 
2012, pp. 16-19] and high level of corruption, especially in the area of public procure-
ment, which creates significant obstacles to the implementation of any governmental 
action, including implementation of import substitution policy.
Pobrane z czasopisma Annales H - Oeconomia http://oeconomia.annales.umcs.pl
Data: 04/08/2020 18:30:44
UM
CS
47MODERN TECHNOLOGIES IN IMPORT SUBSTITUTION POLICY…  
3.  Modern technologies in import substitution policy  
on pharmaceutical market
In the project Concept of the State Target Program “Development of import-substi-
tuting industries in Ukraine and substitution of imported medicines by domestic ones, 
including biotech drugs and vaccines” in 2011–2021 years procurement of medicines 
was one of the most important areas of public policy. The first priority of state action 
in this area is the elimination of corruption during the tender procedures. According 
to independent experts, from 30% to 60% of the budget is “washed out” because of 
application of corruption schemes (based on an annual assessment of the level of trans-
parency in 2013 Ukraine ranked 144 place – gaining 25 points out of 100 and has once 
again confirmed its country rating as one with the highest levels of corruption [Indeks 
Spryjnjattja Korupciï 2013]). As a result – there is a total problem of underfunding of 
treatment programs that leads to inefficient use of budget funds on the one hand and on 
the other – to increased morbidity, disability and increased mortality of the population.
In our view, this issue is crucial to the policy of import substitution in the phar-
maceutical industry, it touches directly as public spending and the quality, timeliness 
and availability of public with provision of medicines and requires priority attention.
Summarizing worldwide organization practice and public procurement, including 
the pharmaceutical industry, it can be stated that there are two basic models. The 
first model is based on the principles of electronic commerce (e-commerce) and is 
implemented in import substitution policies in such countries as USA, Mexico, Chile, 
Peru, Poland, the EU, the second – is based on the implementation of the concept of 
“e-government” (i.e. continuous optimization of the delivery of administrative social 
services, political participation of citizens in the state development by changing internal 
and external relationships through technical means, the Internet and modern media) 
and is used in such countries as Australia, Canada, Saudi Arabia. Characteristic 
features of these two models are shown in Table 1.
Taking into account fundamental differences between these models, we believe 
that a critical factor to consider justifying the choice of one of them as the base are:
• the level of commerce, and e-commerce in particular;
• the structure of the economy (the amount of the public sector in the economy);
• the level of development of internet technology, IKI, telecommunications 
systems;
• the readiness of society to innovations (use of public e-services);
• state funds;
• the time required for modernization.
Analyzing these critical factors it can be argued that, unfortunately, at this stage 
of development, Ukraine is not ready to implement the second model in practice, be-
cause of technological, financial and conceptual backwardness of government. At the 
same time, it can achieve success in the thoughtful application of the first model, in 
particular, using modern information technology and tools of marketing and logistics.
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Table 1. Characteristic features of organization models and public procurement
Characteristic features of organization models and public procurement
1) based on e-trade 2)  based on the implementation of the «e-government» 
concept
• need to introduce a set of technical, techno-
logical, legal support measures
• the need in substantial restructuring of existing IT 
infrastructure (IKI), almost its construction from «0»
• no significant financial investment com-
pared to the second model
• significant financial investment into the construction of 
IKI and full modernization of processes of interaction 
with other state entities
• independent of the level informatization of 
society and business
• the dependence from the critical set of «electronic 
citizens» (e-citizens) and «Electronic Enterprises» 
(e-business) to obtain a sustainable impact on internal 
efficiency and transparency of public administration
• short-term implementation • long-term implementation process
• extensive use of marketing, information 
technology • wide use of «cloud» technologies (cloud computing)
problem of transparency and safety of data
Source: Author’s own study
In particular, the application of advanced information technologies and modern 
marketing (as part of the concept of macro marketing) in the above-mentioned Con-
cept of the State program of development of import substitution industries in Ukraine 
systemic measures in public procurement of medicines is given in Table 2.
However, we believe that the outlined list of systematic measures is not complete, 
because it is based only on the use of one-way interaction model “business-state’’ 
(B2G – business-to-government), in which the state acts as a recipient of goods and 
services from businesses and does not consider other models of interaction, in which 
the state acts as the service provider, “state – consumer» (G2C – government-to-
-citizen), ‘’state – business” (G2B – government-to-business), and model of interaction 
of bodies of state administration between themselves (G2G – Engl. government-to-
-government). In the pharmaceutical industry it is of particular relevance, because 
the main objective of public procurement is to meet the needs of the population with 
respect to quality, safe and affordable medicines.
Integration in the public procurement system of all models of interaction, in 
which the state acts as the provider and the recipient and the products / services using 
updated logistics technologies in the organization of public procurement and drug 
delivery to end-users (as part of macro logistics). Using logistic concept in the public 
procurement system will help significantly improve the efficiency of the competitive 
procurement for state needs on the basis of “consistency, integrity, optimizing of total 
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expenses,” that is, through the consideration of processes in the complex from syste-
matic positions, providing: economy; efficiency of procurement; liquidation of abuse.
Table 2. Scope of application of advanced information technologies  
and modern marketing technologies in the public procurement system of medicines
Systematic actions in the field of public procurement of medicines  
according to the draft Concept
Scope of application:
of advanced 
information 
technologies
of modern 
marketing 
technologies
• Development of a system of monitoring and analyzing of the needs of the 
population of Ukraine in important medicines + +
• Development of transparent procedure of amendments to the list of medi-
cines for public procurement + –
• Creation of a unique electronic database of public procurement of medici-
nes
+ +
• Giving preferences to national companies – –
• Improving the regulatory basis for the tender procurement mechanism – –
• Recovery of the mechanism of state orders during procurement of drugs 
for budget funds recognizing the rational use of effective, safe, quality and 
affordable medicines within the state target programs in health state needs
+ +
• Making changes in the list of remedies of domestic and foreign production, 
which can be purchased by schools and health care institutions, fully or 
partially funded from state and local governments
– +
• Making amendments to the National List of Essential Medicines and 
Medical Products, to provide the substitution of imported medicines with 
national ones under the benchmark analysis
– +
Source: Author’s own study
Relevant examples of the application of logistics technologies are: development 
of evaluation system of competitive proposals aimed at minimizing the risk of the 
state customer when concluding a contract for the supply of goods and services of 
inadequate quality (justification of the choice of suppliers for multiobjective approach); 
decision on the compromise – eliminating of conflict objectives of the institution and 
its customers); decisions about the optimal parties of orders concerning the optimi-
zation of processes of transportation, warehousing, storage of goods purchased and 
their subsequent delivery to end users and so on.
In turn, the use of information technology should envisage: the creation of 
a single integrated information infrastructure, electronic data interchange, electronic 
databases, introduction of electronic document circulation (within the Ministry of 
Health, Ministry of Health between subordinate and medical institutions, between 
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the Ministry of Health, universities and other authorities), the use of modern types 
of software, selection of which is carried out according to such criteria as: simplicity, 
transparency and openness. And the use of marketing techniques, we believe, requires 
the creation of information and marketing center (IMC), which would be entrusted 
with the following functions: 1. Organizer of electronic trading and competition for 
clients (public institutions); 2. Development of monitoring and analysis of requirements 
of the population of Ukraine of important medicines and the formation of requests 
for purchase of goods / services of specified level of quality, safety, availability and 
prices in accordance with existing financial opportunities; 3. Providing support 
bidding procedure (calculation of obligations of participants, financial calculations, 
transaction support, interaction with insurance companies, transportation infra-
structure); 4. Providing clients with integrated marketing services to promote their 
products; 5. Consulting clients on legal issues and the most effective use of tools and 
infrastructure of IMC to solve their problems.
Overall, the design of a process of public procurement of medicines, which is built 
on the integration of all models of interaction in which the state acts as a provider 
and a recipient of goods / services can be presented in Fig. 2.
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Fig. 2. The integrated process of public procurement of medicines and place  
in this process of information, marketing and logistics technologies
Source: Author’s own study
Therefore, a public procurement system is a complex process of interaction be-
tween authorities and businesses and consumers through various legislatively defined 
procedures for the most efficient use of budget funds in the process. An important role 
in this process belongs to the use of information, marketing and logistics technologies 
that make opening prospects of modernization of the existing system of public pro-
curement of medicines on the principles of transparency, openness, competitiveness, 
efficiency and accountability.
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Conclusions
Problem of import substitution is actualized due to the high level of foreign trade 
deficit and slowing their countries in dynamics of exports. The development of the 
pharmaceutical industry, support for domestic producers have a great importance for the 
health system in the world, their independence from imported goods and supporting of 
the economy. This process should be based on an objective analysis of the possibilities 
of modern enterprises and scientific base, accompanied by a thorough financial and 
economic analysis and must not be contrary to the international recommendations 
on providing citizens with quality drugs with proven effectiveness and safety for an 
affordable price.
International experience in the policy of import substitution shows, that it can 
be effective when the national pharmaceutical industry based on its own resources, 
scientific and production potential will be able to meet the needs of the population 
in imported medicines. The process of import substitution should be made carefully, 
with minimization of possible negative consequences for consumers of drugs.
A key problem in implementing the policy of import substitution in the pharma-
ceutical industry, which directly affects as public spending as the quality, timeliness 
and availability of drugs to ensure people are overcoming corruption in the sphere 
of public procurement of medicines. By implementing the model of e-commerce 
Ukraine can achieve significant progress in solving this problem through the use of 
modern information technology and marketing and logistics tools.
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Modern technologies in import substitution policy on pharmaceutical market
The article deals with the nature and characteristics of import substitution policy in the pharma-
ceutical market. It displays advantages and disadvantages of implementation of import substitution. The 
foreign experience of state regulation of the pharmaceutical industry is analyzed in the application of 
the policy of import substitution. It shows integration process of public procurement of medicines on the 
basis of all models of interaction, in which the state acts as the provider and the recipient of products / 
services. The application of advanced information and advanced marketing and logistics technologies 
in supporting this process is identified.
Nowoczesne technologie w polityce substytucji importu na rynku farmaceutycznym
W artykule poruszono problematykę charakteru i cech polityki substytucji importu na rynku 
farmaceutycznym. Wskazano zalety i wady wdrożenia tego rozwiązania. Przeanalizowano zagranicz-
ne doświadczenia w tym zakresie. Artykuł pokazuje proces integracji zamówień publicznych leków 
na podstawie wszystkich modeli interakcji, w których państwo występuje jako dostawca i odbiorca 
produktów/usług. Zidentyfikowano także zastosowanie skomplikowanych technologii informacyjnych 
zaawansowanego marketingu i technologii logistycznych wspierających ten proces.
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